TY  - JOUR
AU  - Čolović, Nataša
AU  - Đorđević, Vesna
AU  - Radojković, Milica
AU  - Karan-Đurašević, Teodora
AU  - Tošić, Nataša
PY  - 2023
UR  - https://doiserbia.nb.rs/Article.aspx?ID=0370-81792300100C
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2292
AB  - Introduction. Chromosomal numerical aberrations are very common in hematological malignancies, but near-tetraploidy (80-104 chromosomes) is rare in myeloid lineage malignancies, with only a few cases reported in myelodysplastic syndrome (MDS). Due to a small number of cases with this rare cytogenetic abnormality, clinicopathological significance of near-tetraploidy in MDS is still unknown. In this case report we present a case of de novo MDS patient with near-tetraploidy in association with TP53 mutation, and we aimed to elucidate the prognostic significance of this rare genetic feature. Case Outline. In August of 2018 a 71-year-old male presented with severe anemia, thrombocytopenia, and leucopenia and enlarged spleen. Laboratory data were as follows: hemoglobin (Hb) 93 g/L, white blood cells (WBC) 2.8×109/L and platelets 23x109/L. The bone marrow aspirate was hypercellular, megakaryocytes were not found, granulocytic cells were 15% with signs of dysplasia, with 16% of blast cells without Auer rods. The finding was in correlation with diagnosis of MDS, type RAEB2 which was also confirmed by immunophenotyping. Cytogenetic finding was near-tetraploidy (48,XY+mar[10]/92,XXYY[10]), and TP53 mutational analysis showed the presence of mutation in exon 8 (p.D281A; c.842 A>C). The patient received from time-to-time packed red blood cells and platelets, and died four months after initial diagnosis. Conclusion. Near-tetraploidy associated with TP53 mutation has been described only in few MDS cases. Results of these reports including ours suggest that the association of TP53 mutation and near-tetra polyploidy is a poor prognostic factor.
AB  - Нумеричке аберације хромозома су веома честе код хематолошких малигнитета, али су приближне тетраплои- дије (80–104 хромозома) ретке у малигнитетима мијелоидне лозе, са само неколико случајева пријављених у мијелоди- спластичком синдрому (МДС). Због малог броја случајева са овом ретком цитогенетском абнормалношћу, клиничко- -патолошки значај приближне тетраплоидије у МДС-у је још увек непознат. Овим приказом de novo болесника са МДС-ом, са приближном тетраплоидијом и мутацијом у гену TP53, циљ нам је био да расветлимо прогностички значај ове рет- ке генетске карактеристикe. Приказ болесника Приказан је 71-годишњи болесник који је у августу 2018. године развио симптоме тешке анемије, тромбоцитопеније, леукопеније и увећане слезине. Лабо- раторијске анализе су показале следеће: хемоглобин 93 g/L, леукоцити 2,8 × 109 /L и тромбоцити 23 × 109 /L. Аспират коштане сржи је био хиперћелијски, мегакариоцити нису на- ђени, 15% гранулоцитa је било са знацима дисплазије, 16% бластa без Ауерових штапића. Налаз је одговарао дијагнози МДС-а, типа рефракторне анемије са вишком бласта 2, што је потврђено и имунолошком фенотипизацијом. Цитогенет- ском анализом утврђено је присуство приближне тетрапло- идије (48,XY+mar10/92,XXYY[10]), а анализа мутација у гену TP53 показала је присуство мутације у егзону 8 (p.D281A; c.842 A > C). Болесник је по потреби примао трансфузију еритроцита и тромбоците, а умро је четири месеца након почетне дијагнозе. Закључак Присуство приближне тетраплоидије удружене са мутацијама у гену TP53 описано је само у неколико слу- чајева МДС-а. Резултати ових случајева, као и наши резул- тати, указују на то да приближна тетраплоидија повезана са присуством мутација у гену TP53 представља фактор лоше прогнозе.
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
T1  - Мијелодиспластични синдром са приближном тетраплоидијом удруженом са мутацијом гена TP53 – редак случај
EP  - n/a
IS  - n/a
SP  - n/a
DO  - 10.2298/SARH230728100C
ER  - 

@article{
author = "Čolović, Nataša and Đorđević, Vesna and Radojković, Milica and Karan-Đurašević, Teodora and Tošić, Nataša",
year = "2023",
abstract = "Introduction. Chromosomal numerical aberrations are very common in hematological malignancies, but near-tetraploidy (80-104 chromosomes) is rare in myeloid lineage malignancies, with only a few cases reported in myelodysplastic syndrome (MDS). Due to a small number of cases with this rare cytogenetic abnormality, clinicopathological significance of near-tetraploidy in MDS is still unknown. In this case report we present a case of de novo MDS patient with near-tetraploidy in association with TP53 mutation, and we aimed to elucidate the prognostic significance of this rare genetic feature. Case Outline. In August of 2018 a 71-year-old male presented with severe anemia, thrombocytopenia, and leucopenia and enlarged spleen. Laboratory data were as follows: hemoglobin (Hb) 93 g/L, white blood cells (WBC) 2.8×109/L and platelets 23x109/L. The bone marrow aspirate was hypercellular, megakaryocytes were not found, granulocytic cells were 15% with signs of dysplasia, with 16% of blast cells without Auer rods. The finding was in correlation with diagnosis of MDS, type RAEB2 which was also confirmed by immunophenotyping. Cytogenetic finding was near-tetraploidy (48,XY+mar[10]/92,XXYY[10]), and TP53 mutational analysis showed the presence of mutation in exon 8 (p.D281A; c.842 A>C). The patient received from time-to-time packed red blood cells and platelets, and died four months after initial diagnosis. Conclusion. Near-tetraploidy associated with TP53 mutation has been described only in few MDS cases. Results of these reports including ours suggest that the association of TP53 mutation and near-tetra polyploidy is a poor prognostic factor., Нумеричке аберације хромозома су веома честе код хематолошких малигнитета, али су приближне тетраплои- дије (80–104 хромозома) ретке у малигнитетима мијелоидне лозе, са само неколико случајева пријављених у мијелоди- спластичком синдрому (МДС). Због малог броја случајева са овом ретком цитогенетском абнормалношћу, клиничко- -патолошки значај приближне тетраплоидије у МДС-у је још увек непознат. Овим приказом de novo болесника са МДС-ом, са приближном тетраплоидијом и мутацијом у гену TP53, циљ нам је био да расветлимо прогностички значај ове рет- ке генетске карактеристикe. Приказ болесника Приказан је 71-годишњи болесник који је у августу 2018. године развио симптоме тешке анемије, тромбоцитопеније, леукопеније и увећане слезине. Лабо- раторијске анализе су показале следеће: хемоглобин 93 g/L, леукоцити 2,8 × 109 /L и тромбоцити 23 × 109 /L. Аспират коштане сржи је био хиперћелијски, мегакариоцити нису на- ђени, 15% гранулоцитa је било са знацима дисплазије, 16% бластa без Ауерових штапића. Налаз је одговарао дијагнози МДС-а, типа рефракторне анемије са вишком бласта 2, што је потврђено и имунолошком фенотипизацијом. Цитогенет- ском анализом утврђено је присуство приближне тетрапло- идије (48,XY+mar10/92,XXYY[10]), а анализа мутација у гену TP53 показала је присуство мутације у егзону 8 (p.D281A; c.842 A > C). Болесник је по потреби примао трансфузију еритроцита и тромбоците, а умро је четири месеца након почетне дијагнозе. Закључак Присуство приближне тетраплоидије удружене са мутацијама у гену TP53 описано је само у неколико слу- чајева МДС-а. Резултати ових случајева, као и наши резул- тати, указују на то да приближна тетраплоидија повезана са присуством мутација у гену TP53 представља фактор лоше прогнозе.",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation, Мијелодиспластични синдром са приближном тетраплоидијом удруженом са мутацијом гена TP53 – редак случај",
pages = "n/a-n/a",
number = "n/a",
doi = "10.2298/SARH230728100C"
}

Čolović, N., Đorđević, V., Radojković, M., Karan-Đurašević, T.,& Tošić, N.. (2023). Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation. in Srpski arhiv za celokupno lekarstvo(n/a), n/a-n/a.
https://doi.org/10.2298/SARH230728100C

Čolović N, Đorđević V, Radojković M, Karan-Đurašević T, Tošić N. Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation. in Srpski arhiv za celokupno lekarstvo. 2023;(n/a):n/a-n/a.
doi:10.2298/SARH230728100C .

Čolović, Nataša, Đorđević, Vesna, Radojković, Milica, Karan-Đurašević, Teodora, Tošić, Nataša, "Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation" in Srpski arhiv za celokupno lekarstvo, no. n/a (2023):n/a-n/a,
https://doi.org/10.2298/SARH230728100C . .

TY  - JOUR
AU  - Vučićević, Ksenija
AU  - Jakovljević, Vladimir
AU  - Čolović, Nataša
AU  - Tošić, Nataša
AU  - Kostić, Tatjana
AU  - Glumac, Irena
AU  - Pavlović, Sonja
AU  - Karan-Đurašević, Teodora
AU  - Čolović, Milica
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/982
AB  - Uvod: Rezistencija na apoptozu koja karakteriše maligne B limfocite in vivo u hroničnoj limfocitnoj leukemiji (HLL) delimično je uzrokovana unutrašnjim poremecajima apoptotske mašinerije u ovim celijama. Ti poremecaji su rezultat genetičkih promena i aberantne ekspresije regulatora procesa apoptoze, među kojima ključnu ulogu imaju članovi Bcl2 familije. Cilj: Cilj ove studije je bio da se ispita udruženost nivoa ekspresije proapoptotskog Bax gena, kao i Bcl2/Bax odnosa, sa kliničkim karakteristikama bolesnika sa HLL kao i molekularnim prognostičkim markerima, i to mutacionim statusom rearanžiranih gena za teške lance imunoglobulina (IGHV) i ekspresijom gena za lipoproteinsku lipazu (LPL). Metode: Analizirana je ekspresija Bax iRNK i Bcl2/Bax iRNK odnos u mononuklearnim celijama periferne krvi 58 bolesnika sa HLL i 10 zdravih kontrola metodom reverzne transkripcije i lančane reakcije polimeraze u realnom vremenu (qRT-PCR). Rezultati: Detektovana je povišena ekspresija Bax gena u HLL uzorcima u odnosu na kontrolne uzorke (p=0,003), kao i povišen Bcl2/Bax odnos (p= lt 0,001). Kada je u pitanju udruženost sa prognostičkim markerima, Bcl2/Bax odnos je ispoljio negativnu korelaciju sa vremenom udvostručavanja broja limfocita (r=-0,307; p=0,0451), dok je visoka ekspresija Bax bila povezana sa LPL-pozitivnim statusom (p=0,035). I ekspresija Bax gena i Bcl2/Bax odnos su bili viši kod bolesnika sa nemutiranim u odnosu na bolesnike sa mutiranim IGHV genima, ali nije dostignuta statistička značajnost. Zaključak: Rezultati ove studije ukazuju na mogucu ulogu poremecene ekspresije Bcl2 i Bax gena, koja dovodi do visokog Bcl2/Bax odnosa u leukemijskim celijama, u patogenezi i kliničkom toku HLL.
AB  - Background: In chronic lymphocytic leukemia (CLL), in vivo apoptotic resistance of malignant B lymphocytes results, in part, from the intrinsic defects of their apoptotic machinery. These include genetic alterations and aberrant expression of many apoptosis regulators, among which the Bcl2 family members play a central role. Aim: The aim of this study was to investigate the association of pro-apoptotic Bax gene expression and Bcl2/Bax ratio with the clinical features of CLL patients as well as with molecular prognostic markers, namely the mutational status of rearranged immunoglobulin heavy variable (IGHV) genes and lipoprotein lipase (LPL) gene expression. Methods: We analyzed the expression of Bax mRNA and Bcl2/Bax mRNA ratio in the peripheral blood mononuclear cells of 58 unselected CLL patients and 10 healthy controls by the quantitative reverse-transcriptase polymerase chain reaction. Results: We detected significant Bax gene overexpression in CLL samples compared to non-leukemic samples (p=0.003), as well as an elevated Bcl2/Bax ratio (p= lt 0.001). Regarding the association with prognostic markers, the Bcl2/Bax ratio showed a negative correlation to lymphocyte doubling time (r=-0.307; p=0.0451), while high-level Bax expression was associated with LPL-positive status (p=0.035). Both the expression of Bax and Bcl2/Bax ratio were higher in patients with unmutated vs. mutated IGHV rearrangements, but this difference did not reach statistical significance. Conclusions: Our results suggest that dysregulated expression of Bcl2 and Bax, which leads to a high Bcl2/Bax ratio in leukemic cells, contributes to the pathogenesis and clinical course of CLL.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Udruženost ekspresije Bax gena i Bcl2/Bax odnosa sa kliničkim i molekularnim prognostičkim markerima u hroničnoj limfocitnoj leukemiji
T1  - Association of Bax expression and Bcl2/Bax ratio with clinical and molecular prognostic markers in chronic lymphocytic leukemia
EP  - 157
IS  - 2
SP  - 150
VL  - 35
DO  - 10.1515/jomb-2015-0017
ER  - 

@article{
author = "Vučićević, Ksenija and Jakovljević, Vladimir and Čolović, Nataša and Tošić, Nataša and Kostić, Tatjana and Glumac, Irena and Pavlović, Sonja and Karan-Đurašević, Teodora and Čolović, Milica",
year = "2016",
abstract = "Uvod: Rezistencija na apoptozu koja karakteriše maligne B limfocite in vivo u hroničnoj limfocitnoj leukemiji (HLL) delimično je uzrokovana unutrašnjim poremecajima apoptotske mašinerije u ovim celijama. Ti poremecaji su rezultat genetičkih promena i aberantne ekspresije regulatora procesa apoptoze, među kojima ključnu ulogu imaju članovi Bcl2 familije. Cilj: Cilj ove studije je bio da se ispita udruženost nivoa ekspresije proapoptotskog Bax gena, kao i Bcl2/Bax odnosa, sa kliničkim karakteristikama bolesnika sa HLL kao i molekularnim prognostičkim markerima, i to mutacionim statusom rearanžiranih gena za teške lance imunoglobulina (IGHV) i ekspresijom gena za lipoproteinsku lipazu (LPL). Metode: Analizirana je ekspresija Bax iRNK i Bcl2/Bax iRNK odnos u mononuklearnim celijama periferne krvi 58 bolesnika sa HLL i 10 zdravih kontrola metodom reverzne transkripcije i lančane reakcije polimeraze u realnom vremenu (qRT-PCR). Rezultati: Detektovana je povišena ekspresija Bax gena u HLL uzorcima u odnosu na kontrolne uzorke (p=0,003), kao i povišen Bcl2/Bax odnos (p= lt 0,001). Kada je u pitanju udruženost sa prognostičkim markerima, Bcl2/Bax odnos je ispoljio negativnu korelaciju sa vremenom udvostručavanja broja limfocita (r=-0,307; p=0,0451), dok je visoka ekspresija Bax bila povezana sa LPL-pozitivnim statusom (p=0,035). I ekspresija Bax gena i Bcl2/Bax odnos su bili viši kod bolesnika sa nemutiranim u odnosu na bolesnike sa mutiranim IGHV genima, ali nije dostignuta statistička značajnost. Zaključak: Rezultati ove studije ukazuju na mogucu ulogu poremecene ekspresije Bcl2 i Bax gena, koja dovodi do visokog Bcl2/Bax odnosa u leukemijskim celijama, u patogenezi i kliničkom toku HLL., Background: In chronic lymphocytic leukemia (CLL), in vivo apoptotic resistance of malignant B lymphocytes results, in part, from the intrinsic defects of their apoptotic machinery. These include genetic alterations and aberrant expression of many apoptosis regulators, among which the Bcl2 family members play a central role. Aim: The aim of this study was to investigate the association of pro-apoptotic Bax gene expression and Bcl2/Bax ratio with the clinical features of CLL patients as well as with molecular prognostic markers, namely the mutational status of rearranged immunoglobulin heavy variable (IGHV) genes and lipoprotein lipase (LPL) gene expression. Methods: We analyzed the expression of Bax mRNA and Bcl2/Bax mRNA ratio in the peripheral blood mononuclear cells of 58 unselected CLL patients and 10 healthy controls by the quantitative reverse-transcriptase polymerase chain reaction. Results: We detected significant Bax gene overexpression in CLL samples compared to non-leukemic samples (p=0.003), as well as an elevated Bcl2/Bax ratio (p= lt 0.001). Regarding the association with prognostic markers, the Bcl2/Bax ratio showed a negative correlation to lymphocyte doubling time (r=-0.307; p=0.0451), while high-level Bax expression was associated with LPL-positive status (p=0.035). Both the expression of Bax and Bcl2/Bax ratio were higher in patients with unmutated vs. mutated IGHV rearrangements, but this difference did not reach statistical significance. Conclusions: Our results suggest that dysregulated expression of Bcl2 and Bax, which leads to a high Bcl2/Bax ratio in leukemic cells, contributes to the pathogenesis and clinical course of CLL.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Udruženost ekspresije Bax gena i Bcl2/Bax odnosa sa kliničkim i molekularnim prognostičkim markerima u hroničnoj limfocitnoj leukemiji, Association of Bax expression and Bcl2/Bax ratio with clinical and molecular prognostic markers in chronic lymphocytic leukemia",
pages = "157-150",
number = "2",
volume = "35",
doi = "10.1515/jomb-2015-0017"
}

Vučićević, K., Jakovljević, V., Čolović, N., Tošić, N., Kostić, T., Glumac, I., Pavlović, S., Karan-Đurašević, T.,& Čolović, M.. (2016). Udruženost ekspresije Bax gena i Bcl2/Bax odnosa sa kliničkim i molekularnim prognostičkim markerima u hroničnoj limfocitnoj leukemiji. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 35(2), 150-157.
https://doi.org/10.1515/jomb-2015-0017

Vučićević K, Jakovljević V, Čolović N, Tošić N, Kostić T, Glumac I, Pavlović S, Karan-Đurašević T, Čolović M. Udruženost ekspresije Bax gena i Bcl2/Bax odnosa sa kliničkim i molekularnim prognostičkim markerima u hroničnoj limfocitnoj leukemiji. in Journal of Medical Biochemistry. 2016;35(2):150-157.
doi:10.1515/jomb-2015-0017 .

Vučićević, Ksenija, Jakovljević, Vladimir, Čolović, Nataša, Tošić, Nataša, Kostić, Tatjana, Glumac, Irena, Pavlović, Sonja, Karan-Đurašević, Teodora, Čolović, Milica, "Udruženost ekspresije Bax gena i Bcl2/Bax odnosa sa kliničkim i molekularnim prognostičkim markerima u hroničnoj limfocitnoj leukemiji" in Journal of Medical Biochemistry, 35, no. 2 (2016):150-157,
https://doi.org/10.1515/jomb-2015-0017 . .

TY  - JOUR
AU  - Virijević, Marijana
AU  - Karan-Đurašević, Teodora
AU  - Marjanović, Irena
AU  - Tošić, Nataša
AU  - Mitrović, Mirjana
AU  - Djunić, Irena
AU  - Čolović, Nataša
AU  - Vidović, Ana
AU  - Suvajdžić-Vuković, Nada
AU  - Tomin, Dragica
AU  - Pavlović, Sonja
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/963
AB  - Background. Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes are frequent molecular lesions in acute myeloid leukaemia with normal karyotype (AML-NK). The effects of IDH mutations on clinical features and treatment outcome in AML-NK have been widely investigated, but only a few studies monitored these mutations during follow-up. Patients and methods. In our study samples from 110 adult de novo AML-NK were studied for the presence of IDH1 and IDH2 mutations, their associations with other prognostic markers and disease outcome. We also analyzed the stability of these mutations during the course of the disease in complete remission (CR) and relapse. Results. IDH mutations were found in 25 (23%) patients. IDH+ patients tend to have lower CR rate compared to IDH-patients (44% vs 62.2%, p = 0.152), and had slightly lower disease free survival (12 months vs 17 months; p = 0.091). On the other hand, the presence of IDH mutations had significant impact on overall survival (2 vs 7 months; p = 0.039). The stability of IDH mutations were studied sequentially in 19 IDH+ patients. All of them lost the mutation in CR, and the same IDH mutations were detected in relapsed samples. Conclusions. Our study shows that the presence of IDH mutations confer an adverse effect in AML-NK patients, which in combination with other molecular markers can lead to an improved risk stratification and better treatment. Also, IDH mutations are very stable during the course of the disease and can be potentially used as markers for minimal residual disease detection.
PB  - Walter De Gruyter Gmbh, Berlin
T2  - Radiology and Oncology
T1  - Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype
EP  - 393
IS  - 4
SP  - 385
VL  - 50
DO  - 10.1515/raon-2016-0044
ER  - 

@article{
author = "Virijević, Marijana and Karan-Đurašević, Teodora and Marjanović, Irena and Tošić, Nataša and Mitrović, Mirjana and Djunić, Irena and Čolović, Nataša and Vidović, Ana and Suvajdžić-Vuković, Nada and Tomin, Dragica and Pavlović, Sonja",
year = "2016",
abstract = "Background. Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes are frequent molecular lesions in acute myeloid leukaemia with normal karyotype (AML-NK). The effects of IDH mutations on clinical features and treatment outcome in AML-NK have been widely investigated, but only a few studies monitored these mutations during follow-up. Patients and methods. In our study samples from 110 adult de novo AML-NK were studied for the presence of IDH1 and IDH2 mutations, their associations with other prognostic markers and disease outcome. We also analyzed the stability of these mutations during the course of the disease in complete remission (CR) and relapse. Results. IDH mutations were found in 25 (23%) patients. IDH+ patients tend to have lower CR rate compared to IDH-patients (44% vs 62.2%, p = 0.152), and had slightly lower disease free survival (12 months vs 17 months; p = 0.091). On the other hand, the presence of IDH mutations had significant impact on overall survival (2 vs 7 months; p = 0.039). The stability of IDH mutations were studied sequentially in 19 IDH+ patients. All of them lost the mutation in CR, and the same IDH mutations were detected in relapsed samples. Conclusions. Our study shows that the presence of IDH mutations confer an adverse effect in AML-NK patients, which in combination with other molecular markers can lead to an improved risk stratification and better treatment. Also, IDH mutations are very stable during the course of the disease and can be potentially used as markers for minimal residual disease detection.",
publisher = "Walter De Gruyter Gmbh, Berlin",
journal = "Radiology and Oncology",
title = "Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype",
pages = "393-385",
number = "4",
volume = "50",
doi = "10.1515/raon-2016-0044"
}

Virijević, M., Karan-Đurašević, T., Marjanović, I., Tošić, N., Mitrović, M., Djunić, I., Čolović, N., Vidović, A., Suvajdžić-Vuković, N., Tomin, D.,& Pavlović, S.. (2016). Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. in Radiology and Oncology
Walter De Gruyter Gmbh, Berlin., 50(4), 385-393.
https://doi.org/10.1515/raon-2016-0044

Virijević M, Karan-Đurašević T, Marjanović I, Tošić N, Mitrović M, Djunić I, Čolović N, Vidović A, Suvajdžić-Vuković N, Tomin D, Pavlović S. Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. in Radiology and Oncology. 2016;50(4):385-393.
doi:10.1515/raon-2016-0044 .

Virijević, Marijana, Karan-Đurašević, Teodora, Marjanović, Irena, Tošić, Nataša, Mitrović, Mirjana, Djunić, Irena, Čolović, Nataša, Vidović, Ana, Suvajdžić-Vuković, Nada, Tomin, Dragica, Pavlović, Sonja, "Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype" in Radiology and Oncology, 50, no. 4 (2016):385-393,
https://doi.org/10.1515/raon-2016-0044 . .

TY  - JOUR
AU  - Mitrović, Mirjana
AU  - Suvajdžić, Nada
AU  - Elezović, Ivo
AU  - Bogdanović, Andrija
AU  - Đorđević, Valentina
AU  - Miljić, Predrag
AU  - Djunić, Irena
AU  - Gvozdenov, Maja
AU  - Čolović, Nataša
AU  - Virijević, Marijana
AU  - Leković, Danijela
AU  - Vidović, Ana
AU  - Tomin, Dragica
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/891
AB  - Introduction: Thrombotic events (TE) appear to be more common in acute promyelocytic leukemia (APL) than in other acute leukemias, with reported prevalence ranging from 2 to 10-15%. Materials and Methods: We retrospectively analyzed the data on TE appearance in 63 APL patients. Results: TE occured in 13 (20.6%) cases, four arterial (6.3%) and nine venous (14.3%). TE were more frequently diagnosed after initiation of weekly D-dimer monitoring (7 TE during 20 months vs 6 during 76 months, P = 0.032). Patients with and without venous thrombosis were significantly different regarding female/male ratio (P = 0.046), PT (P = 0.022), a PTT (P = 0.044), ISTH DIC score (P = 0.001), bcr3 (P = 0.02) and FLT3-ITD (P = 0.028) mutation. The most significant risk factor for venous TE occurrence in multivariate analysis was FLT3-ITD mutation (P = 0.034). PAI-1 4G/4G polymorphism was five times more frequent in patients with venous TE than without it (P = 0.05). Regarding risk factors for arterial TE we failed to identify any. Conclusions: We have demonstrated that APL-related TE rate is higher than previously reported and that weekly D-dimer monitoring might help to identify patients with silent thrombosis. Moreover, our study suggests a possible relationship between venous TE occurrence and several laboratory findings (PT, aPTT, ISTH DIC score, bcr3 isoform, FLT3-ITD mutation and PAI 4G/4G). Prophylactic use of heparin might be considered in patients with ISTH DIC score  lt  5, bcr3 isoform, FLT3-ITD mutation and PAI 4G/4G.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - Thrombotic events in acute promyelocytic leukemia
EP  - 593
IS  - 4
SP  - 588
VL  - 135
DO  - 10.1016/j.thromres.2014.11.026
ER  - 

@article{
author = "Mitrović, Mirjana and Suvajdžić, Nada and Elezović, Ivo and Bogdanović, Andrija and Đorđević, Valentina and Miljić, Predrag and Djunić, Irena and Gvozdenov, Maja and Čolović, Nataša and Virijević, Marijana and Leković, Danijela and Vidović, Ana and Tomin, Dragica",
year = "2015",
abstract = "Introduction: Thrombotic events (TE) appear to be more common in acute promyelocytic leukemia (APL) than in other acute leukemias, with reported prevalence ranging from 2 to 10-15%. Materials and Methods: We retrospectively analyzed the data on TE appearance in 63 APL patients. Results: TE occured in 13 (20.6%) cases, four arterial (6.3%) and nine venous (14.3%). TE were more frequently diagnosed after initiation of weekly D-dimer monitoring (7 TE during 20 months vs 6 during 76 months, P = 0.032). Patients with and without venous thrombosis were significantly different regarding female/male ratio (P = 0.046), PT (P = 0.022), a PTT (P = 0.044), ISTH DIC score (P = 0.001), bcr3 (P = 0.02) and FLT3-ITD (P = 0.028) mutation. The most significant risk factor for venous TE occurrence in multivariate analysis was FLT3-ITD mutation (P = 0.034). PAI-1 4G/4G polymorphism was five times more frequent in patients with venous TE than without it (P = 0.05). Regarding risk factors for arterial TE we failed to identify any. Conclusions: We have demonstrated that APL-related TE rate is higher than previously reported and that weekly D-dimer monitoring might help to identify patients with silent thrombosis. Moreover, our study suggests a possible relationship between venous TE occurrence and several laboratory findings (PT, aPTT, ISTH DIC score, bcr3 isoform, FLT3-ITD mutation and PAI 4G/4G). Prophylactic use of heparin might be considered in patients with ISTH DIC score  lt  5, bcr3 isoform, FLT3-ITD mutation and PAI 4G/4G.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Thrombotic events in acute promyelocytic leukemia",
pages = "593-588",
number = "4",
volume = "135",
doi = "10.1016/j.thromres.2014.11.026"
}

Mitrović, M., Suvajdžić, N., Elezović, I., Bogdanović, A., Đorđević, V., Miljić, P., Djunić, I., Gvozdenov, M., Čolović, N., Virijević, M., Leković, D., Vidović, A.,& Tomin, D.. (2015). Thrombotic events in acute promyelocytic leukemia. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 135(4), 588-593.
https://doi.org/10.1016/j.thromres.2014.11.026

Mitrović M, Suvajdžić N, Elezović I, Bogdanović A, Đorđević V, Miljić P, Djunić I, Gvozdenov M, Čolović N, Virijević M, Leković D, Vidović A, Tomin D. Thrombotic events in acute promyelocytic leukemia. in Thrombosis Research. 2015;135(4):588-593.
doi:10.1016/j.thromres.2014.11.026 .

Mitrović, Mirjana, Suvajdžić, Nada, Elezović, Ivo, Bogdanović, Andrija, Đorđević, Valentina, Miljić, Predrag, Djunić, Irena, Gvozdenov, Maja, Čolović, Nataša, Virijević, Marijana, Leković, Danijela, Vidović, Ana, Tomin, Dragica, "Thrombotic events in acute promyelocytic leukemia" in Thrombosis Research, 135, no. 4 (2015):588-593,
https://doi.org/10.1016/j.thromres.2014.11.026 . .

TY  - JOUR
AU  - Vučićević, Ksenija
AU  - Jakovljević, Vladimir
AU  - Sretenović, Jasmina
AU  - Tošić, Nataša
AU  - Kostić, Tatjana
AU  - Glumac, Irena
AU  - Čolović, Milica
AU  - Čolović, Nataša
AU  - Pavlović, Sonja
AU  - Karan-Đurašević, Teodora
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/847
AB  - Hronična limfocitna leukemija (HLL) se manifestuje kao klonska ekspanzija zrelih B limfocita, čija se akumulacija pripisuje prvenstveno poremećajima procesa apoptoze. U HLL su uočene genetičke promene i aberantna ekspresija različitih članova Bcl2 genske familije, koji imaju ključnu ulogu u regulaciji unutrašnjeg, mitohondrijskog puta aktivacije apoptoze. U ovom radu je analizirana ekspresija anti-apoptotskog Bcl2 gena u grupi od 58 pacijenata obolelih od HLL. Metodom kvantitativnog RT-PCRa detektovana je povišena ekspresija Bcl2 mRNA u HLL uzorcima u odnosu na kontrolne uzorke (p= lt 0.001). 'Receiver operating characteristic' (ROC) analiza je pokazala da nivo ekspresije Bcl2 ima visoku moć diskriminacije između pacijenata i zdravih kontrola (A=0.98, 95% CI=0.95-1.009, p lt 0.0001).
AB  - Chronic lymphocytic leukaemia (CLL) manifests as clonal expansion of mature B lymphocytes, whose accumulation is primarily attributed to the dysregulation of apoptosis. Aberrant expression, as well as genetic alterations within various Bcl2 family members and central regulators of the intrinsic, mitochondriamediated apoptotic pathway all hasve been observed in CLL. Here, we report the expression analysis of the anti-apoptotic Bcl2 gene in a cohort of 58 CLL patients. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis revealed a significant overexpression of Bcl2 mRNA in CLL samples compared to control samples (p= lt 0.001). Receiver operating characteristic (ROC) analysis showed that the level of Bcl2 expression exerts a high discriminatory power between patients and healthy subjects (A=0.98, 95% CI=0.95-1.009, p lt 0.0001).
PB  - Univerzitet u Kragujevcu - Fakultet medicinskih nauka, Kragujevac
T2  - Serbian Journal of Experimental and Clinical Research
T1  - Ekspresija Bcl2 gena kod pacijenata sa hroničnom limfocitnom leukemijom
T1  - Expression of the Bcl2 gene in chronic lymphocytic leukaemia patients
EP  - 191
IS  - 3
SP  - 187
VL  - 16
DO  - 10.1515/SJECR-2015-0024
ER  - 

@article{
author = "Vučićević, Ksenija and Jakovljević, Vladimir and Sretenović, Jasmina and Tošić, Nataša and Kostić, Tatjana and Glumac, Irena and Čolović, Milica and Čolović, Nataša and Pavlović, Sonja and Karan-Đurašević, Teodora",
year = "2015",
abstract = "Hronična limfocitna leukemija (HLL) se manifestuje kao klonska ekspanzija zrelih B limfocita, čija se akumulacija pripisuje prvenstveno poremećajima procesa apoptoze. U HLL su uočene genetičke promene i aberantna ekspresija različitih članova Bcl2 genske familije, koji imaju ključnu ulogu u regulaciji unutrašnjeg, mitohondrijskog puta aktivacije apoptoze. U ovom radu je analizirana ekspresija anti-apoptotskog Bcl2 gena u grupi od 58 pacijenata obolelih od HLL. Metodom kvantitativnog RT-PCRa detektovana je povišena ekspresija Bcl2 mRNA u HLL uzorcima u odnosu na kontrolne uzorke (p= lt 0.001). 'Receiver operating characteristic' (ROC) analiza je pokazala da nivo ekspresije Bcl2 ima visoku moć diskriminacije između pacijenata i zdravih kontrola (A=0.98, 95% CI=0.95-1.009, p lt 0.0001)., Chronic lymphocytic leukaemia (CLL) manifests as clonal expansion of mature B lymphocytes, whose accumulation is primarily attributed to the dysregulation of apoptosis. Aberrant expression, as well as genetic alterations within various Bcl2 family members and central regulators of the intrinsic, mitochondriamediated apoptotic pathway all hasve been observed in CLL. Here, we report the expression analysis of the anti-apoptotic Bcl2 gene in a cohort of 58 CLL patients. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis revealed a significant overexpression of Bcl2 mRNA in CLL samples compared to control samples (p= lt 0.001). Receiver operating characteristic (ROC) analysis showed that the level of Bcl2 expression exerts a high discriminatory power between patients and healthy subjects (A=0.98, 95% CI=0.95-1.009, p lt 0.0001).",
publisher = "Univerzitet u Kragujevcu - Fakultet medicinskih nauka, Kragujevac",
journal = "Serbian Journal of Experimental and Clinical Research",
title = "Ekspresija Bcl2 gena kod pacijenata sa hroničnom limfocitnom leukemijom, Expression of the Bcl2 gene in chronic lymphocytic leukaemia patients",
pages = "191-187",
number = "3",
volume = "16",
doi = "10.1515/SJECR-2015-0024"
}

Vučićević, K., Jakovljević, V., Sretenović, J., Tošić, N., Kostić, T., Glumac, I., Čolović, M., Čolović, N., Pavlović, S.,& Karan-Đurašević, T.. (2015). Ekspresija Bcl2 gena kod pacijenata sa hroničnom limfocitnom leukemijom. in Serbian Journal of Experimental and Clinical Research
Univerzitet u Kragujevcu - Fakultet medicinskih nauka, Kragujevac., 16(3), 187-191.
https://doi.org/10.1515/SJECR-2015-0024

Vučićević K, Jakovljević V, Sretenović J, Tošić N, Kostić T, Glumac I, Čolović M, Čolović N, Pavlović S, Karan-Đurašević T. Ekspresija Bcl2 gena kod pacijenata sa hroničnom limfocitnom leukemijom. in Serbian Journal of Experimental and Clinical Research. 2015;16(3):187-191.
doi:10.1515/SJECR-2015-0024 .

Vučićević, Ksenija, Jakovljević, Vladimir, Sretenović, Jasmina, Tošić, Nataša, Kostić, Tatjana, Glumac, Irena, Čolović, Milica, Čolović, Nataša, Pavlović, Sonja, Karan-Đurašević, Teodora, "Ekspresija Bcl2 gena kod pacijenata sa hroničnom limfocitnom leukemijom" in Serbian Journal of Experimental and Clinical Research, 16, no. 3 (2015):187-191,
https://doi.org/10.1515/SJECR-2015-0024 . .

TY  - CONF
AU  - Mitrović, M.
AU  - Tošić, Nataša
AU  - Suvajdžić, Nada
AU  - Djunić, I.
AU  - Vidović, A.
AU  - Virijević, M.
AU  - Čolović, Nataša
AU  - Glumac, Irena
AU  - Kostić, Tatjana 
AU  - Pavlović, Sonja
AU  - Elezović, I.
AU  - Tomin, D.
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/826
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Prognostic impact of wt1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukemia
EP  - 378
SP  - 377
VL  - 100
UR  - https://hdl.handle.net/21.15107/rcub_imagine_826
ER  - 

@conference{
author = "Mitrović, M. and Tošić, Nataša and Suvajdžić, Nada and Djunić, I. and Vidović, A. and Virijević, M. and Čolović, Nataša and Glumac, Irena and Kostić, Tatjana  and Pavlović, Sonja and Elezović, I. and Tomin, D.",
year = "2015",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Prognostic impact of wt1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukemia",
pages = "378-377",
volume = "100",
url = "https://hdl.handle.net/21.15107/rcub_imagine_826"
}

Mitrović, M., Tošić, N., Suvajdžić, N., Djunić, I., Vidović, A., Virijević, M., Čolović, N., Glumac, I., Kostić, T., Pavlović, S., Elezović, I.,& Tomin, D.. (2015). Prognostic impact of wt1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 100, 377-378.
https://hdl.handle.net/21.15107/rcub_imagine_826

Mitrović M, Tošić N, Suvajdžić N, Djunić I, Vidović A, Virijević M, Čolović N, Glumac I, Kostić T, Pavlović S, Elezović I, Tomin D. Prognostic impact of wt1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukemia. in Haematologica-The Hematology Journal. 2015;100:377-378.
https://hdl.handle.net/21.15107/rcub_imagine_826 .

Mitrović, M., Tošić, Nataša, Suvajdžić, Nada, Djunić, I., Vidović, A., Virijević, M., Čolović, Nataša, Glumac, Irena, Kostić, Tatjana , Pavlović, Sonja, Elezović, I., Tomin, D., "Prognostic impact of wt1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukemia" in Haematologica-The Hematology Journal, 100 (2015):377-378,
https://hdl.handle.net/21.15107/rcub_imagine_826 .

TY  - CONF
AU  - Virijević, M.
AU  - Djunić, I.
AU  - Suvajdžić-Vuković, Nada
AU  - Tošić, Nataša
AU  - Novković, A.
AU  - Mitrović, M.
AU  - Čolović, Nataša
AU  - Vidović, A.
AU  - Pavlović, Sonja
AU  - Tomin, D.
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/825
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Favorable prognostic impact of nmp1 mutation in elderly patients with normal karyotype acute myeloid leukemia
EP  - 369
SP  - 369
VL  - 100
UR  - https://hdl.handle.net/21.15107/rcub_imagine_825
ER  - 

@conference{
author = "Virijević, M. and Djunić, I. and Suvajdžić-Vuković, Nada and Tošić, Nataša and Novković, A. and Mitrović, M. and Čolović, Nataša and Vidović, A. and Pavlović, Sonja and Tomin, D.",
year = "2015",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Favorable prognostic impact of nmp1 mutation in elderly patients with normal karyotype acute myeloid leukemia",
pages = "369-369",
volume = "100",
url = "https://hdl.handle.net/21.15107/rcub_imagine_825"
}

Virijević, M., Djunić, I., Suvajdžić-Vuković, N., Tošić, N., Novković, A., Mitrović, M., Čolović, N., Vidović, A., Pavlović, S.,& Tomin, D.. (2015). Favorable prognostic impact of nmp1 mutation in elderly patients with normal karyotype acute myeloid leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 100, 369-369.
https://hdl.handle.net/21.15107/rcub_imagine_825

Virijević M, Djunić I, Suvajdžić-Vuković N, Tošić N, Novković A, Mitrović M, Čolović N, Vidović A, Pavlović S, Tomin D. Favorable prognostic impact of nmp1 mutation in elderly patients with normal karyotype acute myeloid leukemia. in Haematologica-The Hematology Journal. 2015;100:369-369.
https://hdl.handle.net/21.15107/rcub_imagine_825 .

Virijević, M., Djunić, I., Suvajdžić-Vuković, Nada, Tošić, Nataša, Novković, A., Mitrović, M., Čolović, Nataša, Vidović, A., Pavlović, Sonja, Tomin, D., "Favorable prognostic impact of nmp1 mutation in elderly patients with normal karyotype acute myeloid leukemia" in Haematologica-The Hematology Journal, 100 (2015):369-369,
https://hdl.handle.net/21.15107/rcub_imagine_825 .

TY  - CONF
AU  - Mitrović, M.
AU  - Suvajdžić, Nada
AU  - Elezović, I.
AU  - Bogdanović, A.
AU  - Đorđević, Valentina
AU  - Djunić, I.
AU  - Gvozdenov, Maja
AU  - Čolović, Nataša
AU  - Virijević, M.
AU  - Vidović, A.
AU  - Tomin, D.
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/708
PB  - Pergamon-Elsevier Science Ltd, Oxford
C3  - Thrombosis Research
T1  - Risk factors for thrombosis in acute promyelocytic leukemia
EP  - S105
SP  - S104
VL  - 133
DO  - 10.1016/S0049-3848(14)50331-3
ER  - 

@conference{
author = "Mitrović, M. and Suvajdžić, Nada and Elezović, I. and Bogdanović, A. and Đorđević, Valentina and Djunić, I. and Gvozdenov, Maja and Čolović, Nataša and Virijević, M. and Vidović, A. and Tomin, D.",
year = "2014",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Risk factors for thrombosis in acute promyelocytic leukemia",
pages = "S105-S104",
volume = "133",
doi = "10.1016/S0049-3848(14)50331-3"
}

Mitrović, M., Suvajdžić, N., Elezović, I., Bogdanović, A., Đorđević, V., Djunić, I., Gvozdenov, M., Čolović, N., Virijević, M., Vidović, A.,& Tomin, D.. (2014). Risk factors for thrombosis in acute promyelocytic leukemia. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 133, S104-S105.
https://doi.org/10.1016/S0049-3848(14)50331-3

Mitrović M, Suvajdžić N, Elezović I, Bogdanović A, Đorđević V, Djunić I, Gvozdenov M, Čolović N, Virijević M, Vidović A, Tomin D. Risk factors for thrombosis in acute promyelocytic leukemia. in Thrombosis Research. 2014;133:S104-S105.
doi:10.1016/S0049-3848(14)50331-3 .

Mitrović, M., Suvajdžić, Nada, Elezović, I., Bogdanović, A., Đorđević, Valentina, Djunić, I., Gvozdenov, Maja, Čolović, Nataša, Virijević, M., Vidović, A., Tomin, D., "Risk factors for thrombosis in acute promyelocytic leukemia" in Thrombosis Research, 133 (2014):S104-S105,
https://doi.org/10.1016/S0049-3848(14)50331-3 . .

TY  - CONF
AU  - Mitrović, M.
AU  - Tošić, Nataša
AU  - Suvajdžić, Nada
AU  - Djunić, I.
AU  - Vidović, A.
AU  - Virijević, M.
AU  - Čolović, Nataša
AU  - Kostić, Tatjana 
AU  - Glumac, Irena
AU  - Pavlović, Sonja
AU  - Elezović, I.
AU  - Tomin, D.
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/744
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Adverse prognostic significance of wilms tumor gene 1 overexpression in acute promyelocytic leukemia
EP  - 575
SP  - 575
VL  - 99
UR  - https://hdl.handle.net/21.15107/rcub_imagine_744
ER  - 

@conference{
author = "Mitrović, M. and Tošić, Nataša and Suvajdžić, Nada and Djunić, I. and Vidović, A. and Virijević, M. and Čolović, Nataša and Kostić, Tatjana  and Glumac, Irena and Pavlović, Sonja and Elezović, I. and Tomin, D.",
year = "2014",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Adverse prognostic significance of wilms tumor gene 1 overexpression in acute promyelocytic leukemia",
pages = "575-575",
volume = "99",
url = "https://hdl.handle.net/21.15107/rcub_imagine_744"
}

Mitrović, M., Tošić, N., Suvajdžić, N., Djunić, I., Vidović, A., Virijević, M., Čolović, N., Kostić, T., Glumac, I., Pavlović, S., Elezović, I.,& Tomin, D.. (2014). Adverse prognostic significance of wilms tumor gene 1 overexpression in acute promyelocytic leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 99, 575-575.
https://hdl.handle.net/21.15107/rcub_imagine_744

Mitrović M, Tošić N, Suvajdžić N, Djunić I, Vidović A, Virijević M, Čolović N, Kostić T, Glumac I, Pavlović S, Elezović I, Tomin D. Adverse prognostic significance of wilms tumor gene 1 overexpression in acute promyelocytic leukemia. in Haematologica-The Hematology Journal. 2014;99:575-575.
https://hdl.handle.net/21.15107/rcub_imagine_744 .

Mitrović, M., Tošić, Nataša, Suvajdžić, Nada, Djunić, I., Vidović, A., Virijević, M., Čolović, Nataša, Kostić, Tatjana , Glumac, Irena, Pavlović, Sonja, Elezović, I., Tomin, D., "Adverse prognostic significance of wilms tumor gene 1 overexpression in acute promyelocytic leukemia" in Haematologica-The Hematology Journal, 99 (2014):575-575,
https://hdl.handle.net/21.15107/rcub_imagine_744 .

TY  - CONF
AU  - Vidović, A.
AU  - Virijević, M.
AU  - Djunić, I.
AU  - Tomin, D.
AU  - Suvajdžić-Vuković, Nada
AU  - Čolović, Nataša
AU  - Mitrović, M.
AU  - Arsić-Arsenijević, Valentina
AU  - Pavlović, Sonja
AU  - Mihaljević, B.
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/745
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Significance of febrile neutropenia risk score in patients with acute myeloid leukemia
EP  - 575
SP  - 574
VL  - 99
UR  - https://hdl.handle.net/21.15107/rcub_imagine_745
ER  - 

@conference{
author = "Vidović, A. and Virijević, M. and Djunić, I. and Tomin, D. and Suvajdžić-Vuković, Nada and Čolović, Nataša and Mitrović, M. and Arsić-Arsenijević, Valentina and Pavlović, Sonja and Mihaljević, B.",
year = "2014",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Significance of febrile neutropenia risk score in patients with acute myeloid leukemia",
pages = "575-574",
volume = "99",
url = "https://hdl.handle.net/21.15107/rcub_imagine_745"
}

Vidović, A., Virijević, M., Djunić, I., Tomin, D., Suvajdžić-Vuković, N., Čolović, N., Mitrović, M., Arsić-Arsenijević, V., Pavlović, S.,& Mihaljević, B.. (2014). Significance of febrile neutropenia risk score in patients with acute myeloid leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 99, 574-575.
https://hdl.handle.net/21.15107/rcub_imagine_745

Vidović A, Virijević M, Djunić I, Tomin D, Suvajdžić-Vuković N, Čolović N, Mitrović M, Arsić-Arsenijević V, Pavlović S, Mihaljević B. Significance of febrile neutropenia risk score in patients with acute myeloid leukemia. in Haematologica-The Hematology Journal. 2014;99:574-575.
https://hdl.handle.net/21.15107/rcub_imagine_745 .

Vidović, A., Virijević, M., Djunić, I., Tomin, D., Suvajdžić-Vuković, Nada, Čolović, Nataša, Mitrović, M., Arsić-Arsenijević, Valentina, Pavlović, Sonja, Mihaljević, B., "Significance of febrile neutropenia risk score in patients with acute myeloid leukemia" in Haematologica-The Hematology Journal, 99 (2014):574-575,
https://hdl.handle.net/21.15107/rcub_imagine_745 .

TY  - CONF
AU  - Virijević, M.
AU  - Suvajdžić-Vuković, Nada
AU  - Djunić, I.
AU  - Tošić, Nataša
AU  - Novković, A.
AU  - Čolović, Nataša
AU  - Vidović, A.
AU  - Pavlović, Sonja
AU  - Tomin, D.
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/746
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Adverse prognostic impact of IDH mutations on outcome in acute myeloid leukemia with normal karyotype
EP  - 303
SP  - 302
VL  - 99
UR  - https://hdl.handle.net/21.15107/rcub_imagine_746
ER  - 

@conference{
author = "Virijević, M. and Suvajdžić-Vuković, Nada and Djunić, I. and Tošić, Nataša and Novković, A. and Čolović, Nataša and Vidović, A. and Pavlović, Sonja and Tomin, D.",
year = "2014",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Adverse prognostic impact of IDH mutations on outcome in acute myeloid leukemia with normal karyotype",
pages = "303-302",
volume = "99",
url = "https://hdl.handle.net/21.15107/rcub_imagine_746"
}

Virijević, M., Suvajdžić-Vuković, N., Djunić, I., Tošić, N., Novković, A., Čolović, N., Vidović, A., Pavlović, S.,& Tomin, D.. (2014). Adverse prognostic impact of IDH mutations on outcome in acute myeloid leukemia with normal karyotype. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 99, 302-303.
https://hdl.handle.net/21.15107/rcub_imagine_746

Virijević M, Suvajdžić-Vuković N, Djunić I, Tošić N, Novković A, Čolović N, Vidović A, Pavlović S, Tomin D. Adverse prognostic impact of IDH mutations on outcome in acute myeloid leukemia with normal karyotype. in Haematologica-The Hematology Journal. 2014;99:302-303.
https://hdl.handle.net/21.15107/rcub_imagine_746 .

Virijević, M., Suvajdžić-Vuković, Nada, Djunić, I., Tošić, Nataša, Novković, A., Čolović, Nataša, Vidović, A., Pavlović, Sonja, Tomin, D., "Adverse prognostic impact of IDH mutations on outcome in acute myeloid leukemia with normal karyotype" in Haematologica-The Hematology Journal, 99 (2014):302-303,
https://hdl.handle.net/21.15107/rcub_imagine_746 .

TY  - JOUR
AU  - Jurišić, Vladimir
AU  - Pavlović, Sonja
AU  - Čolović, Nataša
AU  - Colović, Milica
PY  - 2013
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/642
AB  - To the editor,
In this letter, we wish to point out the possibility of
transformation of myelofibrosis in acute lymphocytic leukemia without the presence of JAK2V617F mutation.
Myeloproliferative neoplasms (MPN) are hematologic
malignant diseases characterized by a clonal proliferation
of one or several lineages [1]. They represent a phenotypically diverse group of chronic myeloid malignancies
that are characterized by the presence of clonal hematopoiesis and an excessive production of terminally differentiated myeloid blood cells. Typically, they include four
main clinical entities: polycythemia vera (PV), essential
thrombocythemia (ET), primary myelofibrosis (PMF), and
chronic myeloid leukemia (CML). PV, ET, and PMF are
usually subcategorized as bcr-abl-negative MPN. However,
sporadic cases of bcr-abl-positive patients with transformation of primary myelofibrosis were reported but without
JAK2V617F mutation [2].
The prevalence of JAK2V617F mutation [3] differs
between various variants of MF with the higher detection
rate for patients with post-PV MF (91 %) if compared to
PMF (45 %) and post-ET MF (39 %). Some works
emphasize the importance of the predictive role of
JAK2V617F mutation for this transformation. JAK2V617F
mutation is also discussed in myeloproliferative disease and
primary myelofibrosis as well, in respect to clinical prognosis and transformation [4, 5]. The JAK2V617F mutation
was reported to found positive in 7 out of 17 (64 %) analyzed
patients with PMF and with transformation to leukemia. The
risk of transformation to acute leukemia in investigated
patients was around 31 % in JAK-2 positive, but several
studies also indicated possibility of transformation in
JAK-2-negative PMF. However, majority of patients were
transformed to acute myeloid leukemia. We previously
reported possibility of transformation of PMF to acute
lymphocytic leukemia (ALL) [2] and only an additional
case in literature reported transformation of refractory
anemia with ring sideroblasts (RARS) to ALL [4] with
20q- cytogenetic. Patients with PV had also possibility to
transform to PMF, frequently regarding to JAK-2 mutation.
However, no difference in the frequency of transformation
PV patients to acute myeloid leukemia was observed
between the JAK2 positive and JAK2 negative [4].
Here, we want to emphasize the possibility thatPMF can
transform into ALL, probably regarding molecular disturbance in immature hematopoietic precursor cell. Briefly, we
previously reported that patient with 20q- cytogenetic anomaly, which is usually a favorable cytogenetic prognostic factor,
can transform to ALL with Philadelphia-positive finding, but
without JAK2V617F mutation, and with fatal outcome after
10 months [2] pointing out the other factors that can lead to
transformation of PMF into ALL.
Since leukemogenesis is a complex process caused by one
or multiple gene alterations, which perturbs the regulation of
development and maturation of the multipotent hemopoietic
progenitor cells gradually leading to acute leukemia, here we
want to point out that they may have other molecular and
cytogenetic changes except JAK2V617F mutation, which can
be important during transformation. We suggested the continuation of the examination of genetic disturbances in
order to understand a very complex process of transformation
in unstable karyotypes in pre-leukemic conditions
PB  - Humana Press Inc, Totowa
T2  - Medical Oncology
T1  - Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation
IS  - 1
VL  - 30
DO  - 10.1007/s12032-012-0398-2
ER  - 

@article{
author = "Jurišić, Vladimir and Pavlović, Sonja and Čolović, Nataša and Colović, Milica",
year = "2013",
abstract = "To the editor,
In this letter, we wish to point out the possibility of
transformation of myelofibrosis in acute lymphocytic leukemia without the presence of JAK2V617F mutation.
Myeloproliferative neoplasms (MPN) are hematologic
malignant diseases characterized by a clonal proliferation
of one or several lineages [1]. They represent a phenotypically diverse group of chronic myeloid malignancies
that are characterized by the presence of clonal hematopoiesis and an excessive production of terminally differentiated myeloid blood cells. Typically, they include four
main clinical entities: polycythemia vera (PV), essential
thrombocythemia (ET), primary myelofibrosis (PMF), and
chronic myeloid leukemia (CML). PV, ET, and PMF are
usually subcategorized as bcr-abl-negative MPN. However,
sporadic cases of bcr-abl-positive patients with transformation of primary myelofibrosis were reported but without
JAK2V617F mutation [2].
The prevalence of JAK2V617F mutation [3] differs
between various variants of MF with the higher detection
rate for patients with post-PV MF (91 %) if compared to
PMF (45 %) and post-ET MF (39 %). Some works
emphasize the importance of the predictive role of
JAK2V617F mutation for this transformation. JAK2V617F
mutation is also discussed in myeloproliferative disease and
primary myelofibrosis as well, in respect to clinical prognosis and transformation [4, 5]. The JAK2V617F mutation
was reported to found positive in 7 out of 17 (64 %) analyzed
patients with PMF and with transformation to leukemia. The
risk of transformation to acute leukemia in investigated
patients was around 31 % in JAK-2 positive, but several
studies also indicated possibility of transformation in
JAK-2-negative PMF. However, majority of patients were
transformed to acute myeloid leukemia. We previously
reported possibility of transformation of PMF to acute
lymphocytic leukemia (ALL) [2] and only an additional
case in literature reported transformation of refractory
anemia with ring sideroblasts (RARS) to ALL [4] with
20q- cytogenetic. Patients with PV had also possibility to
transform to PMF, frequently regarding to JAK-2 mutation.
However, no difference in the frequency of transformation
PV patients to acute myeloid leukemia was observed
between the JAK2 positive and JAK2 negative [4].
Here, we want to emphasize the possibility thatPMF can
transform into ALL, probably regarding molecular disturbance in immature hematopoietic precursor cell. Briefly, we
previously reported that patient with 20q- cytogenetic anomaly, which is usually a favorable cytogenetic prognostic factor,
can transform to ALL with Philadelphia-positive finding, but
without JAK2V617F mutation, and with fatal outcome after
10 months [2] pointing out the other factors that can lead to
transformation of PMF into ALL.
Since leukemogenesis is a complex process caused by one
or multiple gene alterations, which perturbs the regulation of
development and maturation of the multipotent hemopoietic
progenitor cells gradually leading to acute leukemia, here we
want to point out that they may have other molecular and
cytogenetic changes except JAK2V617F mutation, which can
be important during transformation. We suggested the continuation of the examination of genetic disturbances in
order to understand a very complex process of transformation
in unstable karyotypes in pre-leukemic conditions",
publisher = "Humana Press Inc, Totowa",
journal = "Medical Oncology",
title = "Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation",
number = "1",
volume = "30",
doi = "10.1007/s12032-012-0398-2"
}

Jurišić, V., Pavlović, S., Čolović, N.,& Colović, M.. (2013). Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation. in Medical Oncology
Humana Press Inc, Totowa., 30(1).
https://doi.org/10.1007/s12032-012-0398-2

Jurišić V, Pavlović S, Čolović N, Colović M. Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation. in Medical Oncology. 2013;30(1).
doi:10.1007/s12032-012-0398-2 .

Jurišić, Vladimir, Pavlović, Sonja, Čolović, Nataša, Colović, Milica, "Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation" in Medical Oncology, 30, no. 1 (2013),
https://doi.org/10.1007/s12032-012-0398-2 . .

TY  - JOUR
AU  - Karan-Đurašević, Teodora
AU  - Palibrk, Vuk
AU  - Zukić, Branka
AU  - Spasovski, Vesna
AU  - Marjanović, Irena
AU  - Colović, Milica
AU  - Čolović, Nataša
AU  - Jurisić, Vladimir
AU  - Scorilas, Andreas
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2013
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/641
AB  - Dysregulation of apoptosis is a distinctive feature of chronic lymphocytic leukemia (CLL), although a unique mechanism underlying apoptosis resistance of CLL B lymphocytes has not been identified yet. Aberrant expression as well as genetic and epigenetic alterations of numerous genes involved in different pathways of apoptosis regulation has been described in CLL. Here, we report the expression analysis of Bcl2L12 (Bcl2-like 12), a novel apoptotic gene belonging to Bcl2 family, in 58 Serbian CLL patients. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis revealed a significant overexpression of Bcl2L12 mRNA in CLL samples compared to non-leukemic samples, implying its role in the pathogenesis of the disease. Receiver operating characteristic (ROC) analysis showed that Bcl2L12 expression efficiently discriminates CLL cases from healthy controls. However, relatively homogenous Bcl2L12 mRNA expression among patients did not reflect their clinical characteristics (with the exception of lactate dehydrogenase status and time from diagnosis to treatment) and failed to show association with the most informative prognostic markers, namely the mutational status of rearranged immunoglobulin heavy chain variable region genes, CD38 and lipoprotein lipase gene (LPL) expression.
PB  - Humana Press Inc, Totowa
T2  - Medical Oncology
T1  - Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers
IS  - 1
VL  - 30
DO  - 10.1007/s12032-012-0405-7
ER  - 

@article{
author = "Karan-Đurašević, Teodora and Palibrk, Vuk and Zukić, Branka and Spasovski, Vesna and Marjanović, Irena and Colović, Milica and Čolović, Nataša and Jurisić, Vladimir and Scorilas, Andreas and Pavlović, Sonja and Tošić, Nataša",
year = "2013",
abstract = "Dysregulation of apoptosis is a distinctive feature of chronic lymphocytic leukemia (CLL), although a unique mechanism underlying apoptosis resistance of CLL B lymphocytes has not been identified yet. Aberrant expression as well as genetic and epigenetic alterations of numerous genes involved in different pathways of apoptosis regulation has been described in CLL. Here, we report the expression analysis of Bcl2L12 (Bcl2-like 12), a novel apoptotic gene belonging to Bcl2 family, in 58 Serbian CLL patients. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis revealed a significant overexpression of Bcl2L12 mRNA in CLL samples compared to non-leukemic samples, implying its role in the pathogenesis of the disease. Receiver operating characteristic (ROC) analysis showed that Bcl2L12 expression efficiently discriminates CLL cases from healthy controls. However, relatively homogenous Bcl2L12 mRNA expression among patients did not reflect their clinical characteristics (with the exception of lactate dehydrogenase status and time from diagnosis to treatment) and failed to show association with the most informative prognostic markers, namely the mutational status of rearranged immunoglobulin heavy chain variable region genes, CD38 and lipoprotein lipase gene (LPL) expression.",
publisher = "Humana Press Inc, Totowa",
journal = "Medical Oncology",
title = "Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers",
number = "1",
volume = "30",
doi = "10.1007/s12032-012-0405-7"
}

Karan-Đurašević, T., Palibrk, V., Zukić, B., Spasovski, V., Marjanović, I., Colović, M., Čolović, N., Jurisić, V., Scorilas, A., Pavlović, S.,& Tošić, N.. (2013). Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. in Medical Oncology
Humana Press Inc, Totowa., 30(1).
https://doi.org/10.1007/s12032-012-0405-7

Karan-Đurašević T, Palibrk V, Zukić B, Spasovski V, Marjanović I, Colović M, Čolović N, Jurisić V, Scorilas A, Pavlović S, Tošić N. Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. in Medical Oncology. 2013;30(1).
doi:10.1007/s12032-012-0405-7 .

Karan-Đurašević, Teodora, Palibrk, Vuk, Zukić, Branka, Spasovski, Vesna, Marjanović, Irena, Colović, Milica, Čolović, Nataša, Jurisić, Vladimir, Scorilas, Andreas, Pavlović, Sonja, Tošić, Nataša, "Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers" in Medical Oncology, 30, no. 1 (2013),
https://doi.org/10.1007/s12032-012-0405-7 . .

TY  - CONF
AU  - Mitrović, M.
AU  - Suvajdžić, Nada
AU  - Tošić, Nataša
AU  - Bogdanović, A.
AU  - Djunić, I.
AU  - Sretenović, A.
AU  - Vidović, A.
AU  - Virijević, M.
AU  - Čolović, Nataša
AU  - Kostić, Tatjana 
AU  - Karan-Đurašević, Teodora
AU  - Glumac, Irena
AU  - Spasovski, Vesna
AU  - Pavlović, Sonja
AU  - Elezović, I.
AU  - Tomin, D.
PY  - 2013
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/680
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Adverse prognostic significance of FLT3 mutations in acute promyelocytic leukemia
EP  - 283
SP  - 282
VL  - 98
UR  - https://hdl.handle.net/21.15107/rcub_imagine_680
ER  - 

@conference{
author = "Mitrović, M. and Suvajdžić, Nada and Tošić, Nataša and Bogdanović, A. and Djunić, I. and Sretenović, A. and Vidović, A. and Virijević, M. and Čolović, Nataša and Kostić, Tatjana  and Karan-Đurašević, Teodora and Glumac, Irena and Spasovski, Vesna and Pavlović, Sonja and Elezović, I. and Tomin, D.",
year = "2013",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Adverse prognostic significance of FLT3 mutations in acute promyelocytic leukemia",
pages = "283-282",
volume = "98",
url = "https://hdl.handle.net/21.15107/rcub_imagine_680"
}

Mitrović, M., Suvajdžić, N., Tošić, N., Bogdanović, A., Djunić, I., Sretenović, A., Vidović, A., Virijević, M., Čolović, N., Kostić, T., Karan-Đurašević, T., Glumac, I., Spasovski, V., Pavlović, S., Elezović, I.,& Tomin, D.. (2013). Adverse prognostic significance of FLT3 mutations in acute promyelocytic leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 98, 282-283.
https://hdl.handle.net/21.15107/rcub_imagine_680

Mitrović M, Suvajdžić N, Tošić N, Bogdanović A, Djunić I, Sretenović A, Vidović A, Virijević M, Čolović N, Kostić T, Karan-Đurašević T, Glumac I, Spasovski V, Pavlović S, Elezović I, Tomin D. Adverse prognostic significance of FLT3 mutations in acute promyelocytic leukemia. in Haematologica-The Hematology Journal. 2013;98:282-283.
https://hdl.handle.net/21.15107/rcub_imagine_680 .

Mitrović, M., Suvajdžić, Nada, Tošić, Nataša, Bogdanović, A., Djunić, I., Sretenović, A., Vidović, A., Virijević, M., Čolović, Nataša, Kostić, Tatjana , Karan-Đurašević, Teodora, Glumac, Irena, Spasovski, Vesna, Pavlović, Sonja, Elezović, I., Tomin, D., "Adverse prognostic significance of FLT3 mutations in acute promyelocytic leukemia" in Haematologica-The Hematology Journal, 98 (2013):282-283,
https://hdl.handle.net/21.15107/rcub_imagine_680 .

TY  - CONF
AU  - Čolović, Nataša
AU  - Vidović, A.
AU  - Đorđević, V.
AU  - Tošić, Nataša
AU  - Kraguljac, N.
AU  - Suvajdžić, Nada
AU  - Djunić, I.
AU  - Virijević, M.
AU  - Pavlović, S.
AU  - Tomin, D.
PY  - 2013
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/686
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Leukemic transformation of multipotent hematopoietic progenitor cell with t(4;11)(q21:q23), mll-af9 fusion product and lineage switch from b acute lymphoblastic to acute monoblastic leukemia (aml
EP  - 533
SP  - 532
VL  - 98
UR  - https://hdl.handle.net/21.15107/rcub_imagine_686
ER  - 

@conference{
author = "Čolović, Nataša and Vidović, A. and Đorđević, V. and Tošić, Nataša and Kraguljac, N. and Suvajdžić, Nada and Djunić, I. and Virijević, M. and Pavlović, S. and Tomin, D.",
year = "2013",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Leukemic transformation of multipotent hematopoietic progenitor cell with t(4;11)(q21:q23), mll-af9 fusion product and lineage switch from b acute lymphoblastic to acute monoblastic leukemia (aml",
pages = "533-532",
volume = "98",
url = "https://hdl.handle.net/21.15107/rcub_imagine_686"
}

Čolović, N., Vidović, A., Đorđević, V., Tošić, N., Kraguljac, N., Suvajdžić, N., Djunić, I., Virijević, M., Pavlović, S.,& Tomin, D.. (2013). Leukemic transformation of multipotent hematopoietic progenitor cell with t(4;11)(q21:q23), mll-af9 fusion product and lineage switch from b acute lymphoblastic to acute monoblastic leukemia (aml. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 98, 532-533.
https://hdl.handle.net/21.15107/rcub_imagine_686

Čolović N, Vidović A, Đorđević V, Tošić N, Kraguljac N, Suvajdžić N, Djunić I, Virijević M, Pavlović S, Tomin D. Leukemic transformation of multipotent hematopoietic progenitor cell with t(4;11)(q21:q23), mll-af9 fusion product and lineage switch from b acute lymphoblastic to acute monoblastic leukemia (aml. in Haematologica-The Hematology Journal. 2013;98:532-533.
https://hdl.handle.net/21.15107/rcub_imagine_686 .

Čolović, Nataša, Vidović, A., Đorđević, V., Tošić, Nataša, Kraguljac, N., Suvajdžić, Nada, Djunić, I., Virijević, M., Pavlović, S., Tomin, D., "Leukemic transformation of multipotent hematopoietic progenitor cell with t(4;11)(q21:q23), mll-af9 fusion product and lineage switch from b acute lymphoblastic to acute monoblastic leukemia (aml" in Haematologica-The Hematology Journal, 98 (2013):532-533,
https://hdl.handle.net/21.15107/rcub_imagine_686 .

TY  - CONF
AU  - Vidović, A.
AU  - Janković, G.
AU  - Tomin, D.
AU  - Suvajdžić, Nada
AU  - Djunić, I.
AU  - Čolović, Nataša
AU  - Virijević, M.
AU  - Mitrović, M.
AU  - Bogdanović, A.
AU  - Kurtović, N.
AU  - Đorđević, V.
AU  - Fekete, M.
AU  - Pavlović, Sonja
AU  - Perunicić, M.
AU  - Mihaljević, B.
PY  - 2013
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/687
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Blast crisis of chronic myeloid leukemia: laboratory, immunophenotypc, and cytogenetic hallmarks and response to therapy
EP  - 561
SP  - 561
VL  - 98
UR  - https://hdl.handle.net/21.15107/rcub_imagine_687
ER  - 

@conference{
author = "Vidović, A. and Janković, G. and Tomin, D. and Suvajdžić, Nada and Djunić, I. and Čolović, Nataša and Virijević, M. and Mitrović, M. and Bogdanović, A. and Kurtović, N. and Đorđević, V. and Fekete, M. and Pavlović, Sonja and Perunicić, M. and Mihaljević, B.",
year = "2013",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Blast crisis of chronic myeloid leukemia: laboratory, immunophenotypc, and cytogenetic hallmarks and response to therapy",
pages = "561-561",
volume = "98",
url = "https://hdl.handle.net/21.15107/rcub_imagine_687"
}

Vidović, A., Janković, G., Tomin, D., Suvajdžić, N., Djunić, I., Čolović, N., Virijević, M., Mitrović, M., Bogdanović, A., Kurtović, N., Đorđević, V., Fekete, M., Pavlović, S., Perunicić, M.,& Mihaljević, B.. (2013). Blast crisis of chronic myeloid leukemia: laboratory, immunophenotypc, and cytogenetic hallmarks and response to therapy. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 98, 561-561.
https://hdl.handle.net/21.15107/rcub_imagine_687

Vidović A, Janković G, Tomin D, Suvajdžić N, Djunić I, Čolović N, Virijević M, Mitrović M, Bogdanović A, Kurtović N, Đorđević V, Fekete M, Pavlović S, Perunicić M, Mihaljević B. Blast crisis of chronic myeloid leukemia: laboratory, immunophenotypc, and cytogenetic hallmarks and response to therapy. in Haematologica-The Hematology Journal. 2013;98:561-561.
https://hdl.handle.net/21.15107/rcub_imagine_687 .

Vidović, A., Janković, G., Tomin, D., Suvajdžić, Nada, Djunić, I., Čolović, Nataša, Virijević, M., Mitrović, M., Bogdanović, A., Kurtović, N., Đorđević, V., Fekete, M., Pavlović, Sonja, Perunicić, M., Mihaljević, B., "Blast crisis of chronic myeloid leukemia: laboratory, immunophenotypc, and cytogenetic hallmarks and response to therapy" in Haematologica-The Hematology Journal, 98 (2013):561-561,
https://hdl.handle.net/21.15107/rcub_imagine_687 .

TY  - CONF
AU  - Jurisić, Vladimir
AU  - Čolović, Nataša
AU  - Pavlović, Sonja
AU  - Colović, Milica
PY  - 2013
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/649
PB  - Spandidos Publ Ltd, Athens
C3  - International Journal of Molecular Medicine
T1  - Analyses of serum VEGF in respect to FLT3 mutation in leukemia patients
EP  - S65
IS  - Suppl. 1
SP  - S65
VL  - 32
UR  - https://hdl.handle.net/21.15107/rcub_imagine_649
ER  - 

@conference{
author = "Jurisić, Vladimir and Čolović, Nataša and Pavlović, Sonja and Colović, Milica",
year = "2013",
publisher = "Spandidos Publ Ltd, Athens",
journal = "International Journal of Molecular Medicine",
title = "Analyses of serum VEGF in respect to FLT3 mutation in leukemia patients",
pages = "S65-S65",
number = "Suppl. 1",
volume = "32",
url = "https://hdl.handle.net/21.15107/rcub_imagine_649"
}

Jurisić, V., Čolović, N., Pavlović, S.,& Colović, M.. (2013). Analyses of serum VEGF in respect to FLT3 mutation in leukemia patients. in International Journal of Molecular Medicine
Spandidos Publ Ltd, Athens., 32(Suppl. 1), S65-S65.
https://hdl.handle.net/21.15107/rcub_imagine_649

Jurisić V, Čolović N, Pavlović S, Colović M. Analyses of serum VEGF in respect to FLT3 mutation in leukemia patients. in International Journal of Molecular Medicine. 2013;32(Suppl. 1):S65-S65.
https://hdl.handle.net/21.15107/rcub_imagine_649 .

Jurisić, Vladimir, Čolović, Nataša, Pavlović, Sonja, Colović, Milica, "Analyses of serum VEGF in respect to FLT3 mutation in leukemia patients" in International Journal of Molecular Medicine, 32, no. Suppl. 1 (2013):S65-S65,
https://hdl.handle.net/21.15107/rcub_imagine_649 .

TY  - JOUR
AU  - Karan-Đurašević, Teodora
AU  - Palibrk, Vuk
AU  - Kostić, Tatjana
AU  - Spasovski, Vesna
AU  - Nikčević, Gordana
AU  - Srzentić Dražilov, Sanja
AU  - Colović, Milica
AU  - Čolović, Nataša
AU  - Vidović, Ana
AU  - Antić, Darko
AU  - Mihaljević, Biljana
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/565
AB  - The mutational status and configuration of immunoglobulin heavy variable (IGHV) gene rearrangements was analyzed in 85 Serbian patients with chronic lymphocytic leukemia (CLL). We found that 55.3% of cases belonged to mutated and 44.7% to unmutated CLL, progressive disease predominating in the unmutated subset. IGHV gene use resembled that obtained for Mediterranean countries, except for underrepresentation of the IGHV4 subgroup in our cohort. Background: Chronic lymphocytic leukemia (CLL) results from the clonal expansion of mature B lymphocytes and is characterized by extreme clinical heterogeneity. One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. Biased IGHV gene use between M-CLL and U-CLL clones, as well as population differences in the IGHV gene repertoire have been reported. Patients and Methods: In this study, mutational status and configuration of IGHV-IGHD-IGHJ rearrangements in 85 Serbian patients were analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR) and sequencing methodology. Results: We found that 55.3% of cases belonged to M-CLL and 44.7% belonged to U-CLL, with progressive disease predominating in the unmutated subset. Most frequently expressed was the IGHV3 subgroup (55.7%), followed by IGHV1 (27.3%), IGHV4 (12.5%), IGHV5 (2.3%), IGHV2 (1.1%), and IGHV6 (1.1%). The distribution of IGHD subgroups was as follows: IGHD3, 39.1%; IGHD2, 21.8%; IGHD6, 12.6%; IGHD1, 10.3%; IGHD4, 8%; IGHD5, 6.9%; and IGHD7, 1.1%. The most frequent IGHJ gene was IGHJ4 (48.9%), followed by IGHJ6 (28.4%), IGHJ3 (11.4%), and IGHJ5 (11.4%). In 15.3% of cases, heavy complementarity-determining region 3 (VH CDR3) amino acid sequences could be assigned to previously defined stereotyped clusters. Conclusions: Our study showed a strong correlation between IGHV gene mutational status and clinical course of CLL. IGHV gene use was comparable to that obtained for Mediterranean countries, with the exception of the IGHV4 subgroup, which was underrepresented in our cohort. Clinical Lymphoma, Myeloma & Leukemia, Vol. 12, No. 4, 252-60
PB  - CIG Media Group, Lp, Dallas
T2  - Clinical Lymphoma Myeloma & Leukemia
T1  - Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia
EP  - 260
IS  - 4
SP  - 252
VL  - 12
DO  - 10.1016/j.clml.2012.03.005
ER  - 

@article{
author = "Karan-Đurašević, Teodora and Palibrk, Vuk and Kostić, Tatjana and Spasovski, Vesna and Nikčević, Gordana and Srzentić Dražilov, Sanja and Colović, Milica and Čolović, Nataša and Vidović, Ana and Antić, Darko and Mihaljević, Biljana and Pavlović, Sonja and Tošić, Nataša",
year = "2012",
abstract = "The mutational status and configuration of immunoglobulin heavy variable (IGHV) gene rearrangements was analyzed in 85 Serbian patients with chronic lymphocytic leukemia (CLL). We found that 55.3% of cases belonged to mutated and 44.7% to unmutated CLL, progressive disease predominating in the unmutated subset. IGHV gene use resembled that obtained for Mediterranean countries, except for underrepresentation of the IGHV4 subgroup in our cohort. Background: Chronic lymphocytic leukemia (CLL) results from the clonal expansion of mature B lymphocytes and is characterized by extreme clinical heterogeneity. One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. Biased IGHV gene use between M-CLL and U-CLL clones, as well as population differences in the IGHV gene repertoire have been reported. Patients and Methods: In this study, mutational status and configuration of IGHV-IGHD-IGHJ rearrangements in 85 Serbian patients were analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR) and sequencing methodology. Results: We found that 55.3% of cases belonged to M-CLL and 44.7% belonged to U-CLL, with progressive disease predominating in the unmutated subset. Most frequently expressed was the IGHV3 subgroup (55.7%), followed by IGHV1 (27.3%), IGHV4 (12.5%), IGHV5 (2.3%), IGHV2 (1.1%), and IGHV6 (1.1%). The distribution of IGHD subgroups was as follows: IGHD3, 39.1%; IGHD2, 21.8%; IGHD6, 12.6%; IGHD1, 10.3%; IGHD4, 8%; IGHD5, 6.9%; and IGHD7, 1.1%. The most frequent IGHJ gene was IGHJ4 (48.9%), followed by IGHJ6 (28.4%), IGHJ3 (11.4%), and IGHJ5 (11.4%). In 15.3% of cases, heavy complementarity-determining region 3 (VH CDR3) amino acid sequences could be assigned to previously defined stereotyped clusters. Conclusions: Our study showed a strong correlation between IGHV gene mutational status and clinical course of CLL. IGHV gene use was comparable to that obtained for Mediterranean countries, with the exception of the IGHV4 subgroup, which was underrepresented in our cohort. Clinical Lymphoma, Myeloma & Leukemia, Vol. 12, No. 4, 252-60",
publisher = "CIG Media Group, Lp, Dallas",
journal = "Clinical Lymphoma Myeloma & Leukemia",
title = "Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia",
pages = "260-252",
number = "4",
volume = "12",
doi = "10.1016/j.clml.2012.03.005"
}

Karan-Đurašević, T., Palibrk, V., Kostić, T., Spasovski, V., Nikčević, G., Srzentić Dražilov, S., Colović, M., Čolović, N., Vidović, A., Antić, D., Mihaljević, B., Pavlović, S.,& Tošić, N.. (2012). Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia. in Clinical Lymphoma Myeloma & Leukemia
CIG Media Group, Lp, Dallas., 12(4), 252-260.
https://doi.org/10.1016/j.clml.2012.03.005

Karan-Đurašević T, Palibrk V, Kostić T, Spasovski V, Nikčević G, Srzentić Dražilov S, Colović M, Čolović N, Vidović A, Antić D, Mihaljević B, Pavlović S, Tošić N. Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia. in Clinical Lymphoma Myeloma & Leukemia. 2012;12(4):252-260.
doi:10.1016/j.clml.2012.03.005 .

Karan-Đurašević, Teodora, Palibrk, Vuk, Kostić, Tatjana, Spasovski, Vesna, Nikčević, Gordana, Srzentić Dražilov, Sanja, Colović, Milica, Čolović, Nataša, Vidović, Ana, Antić, Darko, Mihaljević, Biljana, Pavlović, Sonja, Tošić, Nataša, "Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia" in Clinical Lymphoma Myeloma & Leukemia, 12, no. 4 (2012):252-260,
https://doi.org/10.1016/j.clml.2012.03.005 . .

TY  - JOUR
AU  - Kuzmanović, Milos
AU  - Tošić, Nataša
AU  - Čolović, Nataša
AU  - Karan-Đurašević, Teodora
AU  - Spasovski, Vesna
AU  - Ugrin, Milena
AU  - Nikčević, Gordana
AU  - Suvajdžić-Vuković, Nada
AU  - Tomin, Dragica
AU  - Vidović, Ana
AU  - Virijević, Marijana
AU  - Pavlović, Sonja
AU  - Colović, Milica
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/609
AB  - Based on current findings, the presence of NPM1 mutations in acute myeloid leukemia (AML) patients is associated with an increased probability of complete remission (CR) and better overall survival (OS). We determined the incidence and prognostic relevance of NPM1 mutations, their association with FLT3 and IDH mutations, and other clinical characteristics in Serbian adult AML patients. Samples from 111 adult de novo AML patients, including 73 AML cases with a normal karyotype (NK-AML), were studied. NPM1, FLT3, and IDH mutations were detected by PCR and direct sequencing. NPM1 mutations were detected in 22.5% of patients. The presence of NPM1 mutations predicted a low CR rate and shorter OS. NPM1 mutations showed an association with both FLT3 and IDH mutations. Survival analysis based on NPM1/FLT3 mutational status revealed a lower OS for NPM1(+)/FLT3(-) compared to the NPM1(-)/FLT3(-) group in NK-AML patients. The lack of impact or unfavorable prognostic effect of NPM1 mutations found in this study can be assigned to a small cohort of analyzed AML patients, as can the presence of FLT3 and IDH mutations or other genetic lesions that cooperate with NPM1 mutations influencing prognosis.
PB  - Karger, Basel
T2  - Acta Haematologica
T1  - Prognostic Impact of NPM1 Mutations in Serbian Adult Patients with Acute Myeloid Leukemia
EP  - 212
IS  - 4
SP  - 203
VL  - 128
DO  - 10.1159/000339506
ER  - 

@article{
author = "Kuzmanović, Milos and Tošić, Nataša and Čolović, Nataša and Karan-Đurašević, Teodora and Spasovski, Vesna and Ugrin, Milena and Nikčević, Gordana and Suvajdžić-Vuković, Nada and Tomin, Dragica and Vidović, Ana and Virijević, Marijana and Pavlović, Sonja and Colović, Milica",
year = "2012",
abstract = "Based on current findings, the presence of NPM1 mutations in acute myeloid leukemia (AML) patients is associated with an increased probability of complete remission (CR) and better overall survival (OS). We determined the incidence and prognostic relevance of NPM1 mutations, their association with FLT3 and IDH mutations, and other clinical characteristics in Serbian adult AML patients. Samples from 111 adult de novo AML patients, including 73 AML cases with a normal karyotype (NK-AML), were studied. NPM1, FLT3, and IDH mutations were detected by PCR and direct sequencing. NPM1 mutations were detected in 22.5% of patients. The presence of NPM1 mutations predicted a low CR rate and shorter OS. NPM1 mutations showed an association with both FLT3 and IDH mutations. Survival analysis based on NPM1/FLT3 mutational status revealed a lower OS for NPM1(+)/FLT3(-) compared to the NPM1(-)/FLT3(-) group in NK-AML patients. The lack of impact or unfavorable prognostic effect of NPM1 mutations found in this study can be assigned to a small cohort of analyzed AML patients, as can the presence of FLT3 and IDH mutations or other genetic lesions that cooperate with NPM1 mutations influencing prognosis.",
publisher = "Karger, Basel",
journal = "Acta Haematologica",
title = "Prognostic Impact of NPM1 Mutations in Serbian Adult Patients with Acute Myeloid Leukemia",
pages = "212-203",
number = "4",
volume = "128",
doi = "10.1159/000339506"
}

Kuzmanović, M., Tošić, N., Čolović, N., Karan-Đurašević, T., Spasovski, V., Ugrin, M., Nikčević, G., Suvajdžić-Vuković, N., Tomin, D., Vidović, A., Virijević, M., Pavlović, S.,& Colović, M.. (2012). Prognostic Impact of NPM1 Mutations in Serbian Adult Patients with Acute Myeloid Leukemia. in Acta Haematologica
Karger, Basel., 128(4), 203-212.
https://doi.org/10.1159/000339506

Kuzmanović M, Tošić N, Čolović N, Karan-Đurašević T, Spasovski V, Ugrin M, Nikčević G, Suvajdžić-Vuković N, Tomin D, Vidović A, Virijević M, Pavlović S, Colović M. Prognostic Impact of NPM1 Mutations in Serbian Adult Patients with Acute Myeloid Leukemia. in Acta Haematologica. 2012;128(4):203-212.
doi:10.1159/000339506 .

Kuzmanović, Milos, Tošić, Nataša, Čolović, Nataša, Karan-Đurašević, Teodora, Spasovski, Vesna, Ugrin, Milena, Nikčević, Gordana, Suvajdžić-Vuković, Nada, Tomin, Dragica, Vidović, Ana, Virijević, Marijana, Pavlović, Sonja, Colović, Milica, "Prognostic Impact of NPM1 Mutations in Serbian Adult Patients with Acute Myeloid Leukemia" in Acta Haematologica, 128, no. 4 (2012):203-212,
https://doi.org/10.1159/000339506 . .

TY  - JOUR
AU  - Radojković, Milica
AU  - Tošić, Nataša
AU  - Čolović, Nataša
AU  - Ristić, Slobodan
AU  - Pavlović, Sonja
AU  - Colović, Milica
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/582
AB  - We report a case of de novo acute myeloid leukemia (AML) with unstable FLT3 gene mutations and stable NPM1 mutation. FLT3/D835 and NPM1 (Type A) mutations were detected upon diagnosis. During the relapse, the FLT3/D835 mutation changed to an FLT3/ITD mutation while the NPM1 (Type A) mutation was retained. Cytogenetic analyses showed the normal karyotype at diagnosis and relapse. Our findings raise interesting questions about the significance of these mutations in the leukemogenic process, about their stability during the evolution of the disease, and regarding the selection of appropriate molecular markers for the monitoring of minimal residual disease.
T2  - Annals of Clinical and Laboratory Science
T1  - Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia
EP  - 190
IS  - 2
SP  - 186
VL  - 42
UR  - https://hdl.handle.net/21.15107/rcub_imagine_582
ER  - 

@article{
author = "Radojković, Milica and Tošić, Nataša and Čolović, Nataša and Ristić, Slobodan and Pavlović, Sonja and Colović, Milica",
year = "2012",
abstract = "We report a case of de novo acute myeloid leukemia (AML) with unstable FLT3 gene mutations and stable NPM1 mutation. FLT3/D835 and NPM1 (Type A) mutations were detected upon diagnosis. During the relapse, the FLT3/D835 mutation changed to an FLT3/ITD mutation while the NPM1 (Type A) mutation was retained. Cytogenetic analyses showed the normal karyotype at diagnosis and relapse. Our findings raise interesting questions about the significance of these mutations in the leukemogenic process, about their stability during the evolution of the disease, and regarding the selection of appropriate molecular markers for the monitoring of minimal residual disease.",
journal = "Annals of Clinical and Laboratory Science",
title = "Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia",
pages = "190-186",
number = "2",
volume = "42",
url = "https://hdl.handle.net/21.15107/rcub_imagine_582"
}

Radojković, M., Tošić, N., Čolović, N., Ristić, S., Pavlović, S.,& Colović, M.. (2012). Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia. in Annals of Clinical and Laboratory Science, 42(2), 186-190.
https://hdl.handle.net/21.15107/rcub_imagine_582

Radojković M, Tošić N, Čolović N, Ristić S, Pavlović S, Colović M. Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia. in Annals of Clinical and Laboratory Science. 2012;42(2):186-190.
https://hdl.handle.net/21.15107/rcub_imagine_582 .

Radojković, Milica, Tošić, Nataša, Čolović, Nataša, Ristić, Slobodan, Pavlović, Sonja, Colović, Milica, "Reversal of FLT3 Mutational Status and Sustained Expression of NPM1 Mutation in Paired Presentation, and Relapse Samples in a Patient with Acute Myeloid Leukemia" in Annals of Clinical and Laboratory Science, 42, no. 2 (2012):186-190,
https://hdl.handle.net/21.15107/rcub_imagine_582 .

TY  - JOUR
AU  - Čolović, Nataša
AU  - Tomin, D.
AU  - Vidović, A.
AU  - Tošić, Nataša
AU  - Atkinson, H. D.
AU  - Colović, Milica D.
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/587
AB  - Central nervous system (CNS) involvement in acute promyelocytic leukemia (APL) is rare and tends to be seen mostly following treatment with all-trans retinoic acid (ATRA), due to prolonged patient survival and poor penetration of the drug in the CNS. At least 10% of extramedullary relapses in APL involve the CNS, and associated factors include an increased age, the BCR isoform, the development of differentiation syndrome, a high white cell count at presentation and hemorrhage into the CNS during induction therapy. We present the case of a patient with high-risk APL, CD56+, CD2+ in whom a CNS relapse was diagnosed through the presence of a PML/RAR alpha rearrangement on PCR of the cerebrospinal fluid (CSF).
PB  - Humana Press Inc, Totowa
T2  - Medical Oncology
T1  - Central nervous system relapse in CD56+, FLT3/ITD+ promyelocytic leukemia
EP  - 262
IS  - 1
SP  - 260
VL  - 29
DO  - 10.1007/s12032-011-9834-y
ER  - 

@article{
author = "Čolović, Nataša and Tomin, D. and Vidović, A. and Tošić, Nataša and Atkinson, H. D. and Colović, Milica D.",
year = "2012",
abstract = "Central nervous system (CNS) involvement in acute promyelocytic leukemia (APL) is rare and tends to be seen mostly following treatment with all-trans retinoic acid (ATRA), due to prolonged patient survival and poor penetration of the drug in the CNS. At least 10% of extramedullary relapses in APL involve the CNS, and associated factors include an increased age, the BCR isoform, the development of differentiation syndrome, a high white cell count at presentation and hemorrhage into the CNS during induction therapy. We present the case of a patient with high-risk APL, CD56+, CD2+ in whom a CNS relapse was diagnosed through the presence of a PML/RAR alpha rearrangement on PCR of the cerebrospinal fluid (CSF).",
publisher = "Humana Press Inc, Totowa",
journal = "Medical Oncology",
title = "Central nervous system relapse in CD56+, FLT3/ITD+ promyelocytic leukemia",
pages = "262-260",
number = "1",
volume = "29",
doi = "10.1007/s12032-011-9834-y"
}

Čolović, N., Tomin, D., Vidović, A., Tošić, N., Atkinson, H. D.,& Colović, M. D.. (2012). Central nervous system relapse in CD56+, FLT3/ITD+ promyelocytic leukemia. in Medical Oncology
Humana Press Inc, Totowa., 29(1), 260-262.
https://doi.org/10.1007/s12032-011-9834-y

Čolović N, Tomin D, Vidović A, Tošić N, Atkinson HD, Colović MD. Central nervous system relapse in CD56+, FLT3/ITD+ promyelocytic leukemia. in Medical Oncology. 2012;29(1):260-262.
doi:10.1007/s12032-011-9834-y .

Čolović, Nataša, Tomin, D., Vidović, A., Tošić, Nataša, Atkinson, H. D., Colović, Milica D., "Central nervous system relapse in CD56+, FLT3/ITD+ promyelocytic leukemia" in Medical Oncology, 29, no. 1 (2012):260-262,
https://doi.org/10.1007/s12032-011-9834-y . .

TY  - CONF
AU  - Karan-Đurašević, Teodora
AU  - Palibrk, V.
AU  - Tošić, Nataša
AU  - Kostić, Tatjana 
AU  - Spasovski, Vesna
AU  - Nikčević, Gordana
AU  - Srzentić Dražilov, Sanja
AU  - Glumac, Irena
AU  - Colović, M.
AU  - Čolović, Nataša
AU  - Antić, Darko
AU  - Mihaljević, B.
AU  - Scorilas, A.
AU  - Kontos, C.
AU  - Pavlović, Sonja
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/613
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers
EP  - 298
SP  - 298
VL  - 97
UR  - https://hdl.handle.net/21.15107/rcub_imagine_613
ER  - 

@conference{
author = "Karan-Đurašević, Teodora and Palibrk, V. and Tošić, Nataša and Kostić, Tatjana  and Spasovski, Vesna and Nikčević, Gordana and Srzentić Dražilov, Sanja and Glumac, Irena and Colović, M. and Čolović, Nataša and Antić, Darko and Mihaljević, B. and Scorilas, A. and Kontos, C. and Pavlović, Sonja",
year = "2012",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers",
pages = "298-298",
volume = "97",
url = "https://hdl.handle.net/21.15107/rcub_imagine_613"
}

Karan-Đurašević, T., Palibrk, V., Tošić, N., Kostić, T., Spasovski, V., Nikčević, G., Srzentić Dražilov, S., Glumac, I., Colović, M., Čolović, N., Antić, D., Mihaljević, B., Scorilas, A., Kontos, C.,& Pavlović, S.. (2012). Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 97, 298-298.
https://hdl.handle.net/21.15107/rcub_imagine_613

Karan-Đurašević T, Palibrk V, Tošić N, Kostić T, Spasovski V, Nikčević G, Srzentić Dražilov S, Glumac I, Colović M, Čolović N, Antić D, Mihaljević B, Scorilas A, Kontos C, Pavlović S. Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers. in Haematologica-The Hematology Journal. 2012;97:298-298.
https://hdl.handle.net/21.15107/rcub_imagine_613 .

Karan-Đurašević, Teodora, Palibrk, V., Tošić, Nataša, Kostić, Tatjana , Spasovski, Vesna, Nikčević, Gordana, Srzentić Dražilov, Sanja, Glumac, Irena, Colović, M., Čolović, Nataša, Antić, Darko, Mihaljević, B., Scorilas, A., Kontos, C., Pavlović, Sonja, "Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers" in Haematologica-The Hematology Journal, 97 (2012):298-298,
https://hdl.handle.net/21.15107/rcub_imagine_613 .

TY  - CONF
AU  - Spasovski, Vesna
AU  - Tošić, Nataša
AU  - Nikčević, Gordana
AU  - Stojiljković, Maja
AU  - Zukić, Branka
AU  - Radmilović, Milena
AU  - Karan-Đurašević, Teodora
AU  - Srzentić Dražilov, Sanja
AU  - Čolović, Nataša
AU  - Colović, M.
AU  - Pavlović, Sonja
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/603
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - The 46/1 haplotype is involved in transcriptional regulation of janus kinase 2 gene
EP  - 373
SP  - 372
VL  - 97
UR  - https://hdl.handle.net/21.15107/rcub_imagine_603
ER  - 

@conference{
author = "Spasovski, Vesna and Tošić, Nataša and Nikčević, Gordana and Stojiljković, Maja and Zukić, Branka and Radmilović, Milena and Karan-Đurašević, Teodora and Srzentić Dražilov, Sanja and Čolović, Nataša and Colović, M. and Pavlović, Sonja",
year = "2012",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "The 46/1 haplotype is involved in transcriptional regulation of janus kinase 2 gene",
pages = "373-372",
volume = "97",
url = "https://hdl.handle.net/21.15107/rcub_imagine_603"
}

Spasovski, V., Tošić, N., Nikčević, G., Stojiljković, M., Zukić, B., Radmilović, M., Karan-Đurašević, T., Srzentić Dražilov, S., Čolović, N., Colović, M.,& Pavlović, S.. (2012). The 46/1 haplotype is involved in transcriptional regulation of janus kinase 2 gene. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 97, 372-373.
https://hdl.handle.net/21.15107/rcub_imagine_603

Spasovski V, Tošić N, Nikčević G, Stojiljković M, Zukić B, Radmilović M, Karan-Đurašević T, Srzentić Dražilov S, Čolović N, Colović M, Pavlović S. The 46/1 haplotype is involved in transcriptional regulation of janus kinase 2 gene. in Haematologica-The Hematology Journal. 2012;97:372-373.
https://hdl.handle.net/21.15107/rcub_imagine_603 .

Spasovski, Vesna, Tošić, Nataša, Nikčević, Gordana, Stojiljković, Maja, Zukić, Branka, Radmilović, Milena, Karan-Đurašević, Teodora, Srzentić Dražilov, Sanja, Čolović, Nataša, Colović, M., Pavlović, Sonja, "The 46/1 haplotype is involved in transcriptional regulation of janus kinase 2 gene" in Haematologica-The Hematology Journal, 97 (2012):372-373,
https://hdl.handle.net/21.15107/rcub_imagine_603 .

TY  - CONF
AU  - Virijević, M.
AU  - Djunić, I.
AU  - Novković, A.
AU  - Tošić, Nataša
AU  - Vidović, A.
AU  - Čolović, Nataša
AU  - Đurašinović, Vladislava
AU  - Suvajdžić-Vuković, Nada
AU  - Tomin, D.
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/602
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Prognostic impact of leukocytosis in patients with acute myeloid leukemia and mutated npm1 and flt3-itd
EP  - 509
SP  - 508
VL  - 97
UR  - https://hdl.handle.net/21.15107/rcub_imagine_602
ER  - 

@conference{
author = "Virijević, M. and Djunić, I. and Novković, A. and Tošić, Nataša and Vidović, A. and Čolović, Nataša and Đurašinović, Vladislava and Suvajdžić-Vuković, Nada and Tomin, D.",
year = "2012",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Prognostic impact of leukocytosis in patients with acute myeloid leukemia and mutated npm1 and flt3-itd",
pages = "509-508",
volume = "97",
url = "https://hdl.handle.net/21.15107/rcub_imagine_602"
}

Virijević, M., Djunić, I., Novković, A., Tošić, N., Vidović, A., Čolović, N., Đurašinović, V., Suvajdžić-Vuković, N.,& Tomin, D.. (2012). Prognostic impact of leukocytosis in patients with acute myeloid leukemia and mutated npm1 and flt3-itd. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 97, 508-509.
https://hdl.handle.net/21.15107/rcub_imagine_602

Virijević M, Djunić I, Novković A, Tošić N, Vidović A, Čolović N, Đurašinović V, Suvajdžić-Vuković N, Tomin D. Prognostic impact of leukocytosis in patients with acute myeloid leukemia and mutated npm1 and flt3-itd. in Haematologica-The Hematology Journal. 2012;97:508-509.
https://hdl.handle.net/21.15107/rcub_imagine_602 .

Virijević, M., Djunić, I., Novković, A., Tošić, Nataša, Vidović, A., Čolović, Nataša, Đurašinović, Vladislava, Suvajdžić-Vuković, Nada, Tomin, D., "Prognostic impact of leukocytosis in patients with acute myeloid leukemia and mutated npm1 and flt3-itd" in Haematologica-The Hematology Journal, 97 (2012):508-509,
https://hdl.handle.net/21.15107/rcub_imagine_602 .

TY  - JOUR
AU  - Jurisić, Vladimir
AU  - Pavlović, Sonja
AU  - Čolović, Nataša
AU  - Đorđević, Vesna
AU  - Janković, Gradimir
AU  - Colović, Milica
PY  - 2011
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/525
AB  - Tetraploidy and near-tetraploidy are rare in acute myeloid leukemia (AML), contrary to other hematological disease. In this paper we describe a case of a 52-year-old male with AML associated with tetraploidy, mutation in tyrosine kinase receptor FLT3, and very short survival. At presentation maculopapular rash with crustae, lymphadenopathy, and hepatosplenomegaly was diagnosed. The blasts comprised 80% of marrow nucleated cells (POX negative and PAS finely granular positive). Immunophenotyping done on marrow cells was (CD34, HLA DR, CD14, CD64, CD33, CD11b, and CD15) and correlated with the acute monoblastic leukemia. Detection of FLT3 mutation was done by polymerase chain reaction (PCR). Cytogenetic analysis show: 85-93. XXYY,inc(cp5)/46,XY. Based on these considerations, we suggest the detection of FLT3 mutations as a diagnostic procedure for all AML patients.
PB  - Amer Soc Clinical Pathology, Chicago
T2  - Laboratory Medicine
T1  - Acute Myeloid Leukemia Associated With Near-Tetraploid Karyotype and Mutations in the FLT3 Gene
EP  - 543
IS  - 9
SP  - 540
VL  - 42
DO  - 10.1309/LM6E0CQQPOKXXG4E
ER  - 

@article{
author = "Jurisić, Vladimir and Pavlović, Sonja and Čolović, Nataša and Đorđević, Vesna and Janković, Gradimir and Colović, Milica",
year = "2011",
abstract = "Tetraploidy and near-tetraploidy are rare in acute myeloid leukemia (AML), contrary to other hematological disease. In this paper we describe a case of a 52-year-old male with AML associated with tetraploidy, mutation in tyrosine kinase receptor FLT3, and very short survival. At presentation maculopapular rash with crustae, lymphadenopathy, and hepatosplenomegaly was diagnosed. The blasts comprised 80% of marrow nucleated cells (POX negative and PAS finely granular positive). Immunophenotyping done on marrow cells was (CD34, HLA DR, CD14, CD64, CD33, CD11b, and CD15) and correlated with the acute monoblastic leukemia. Detection of FLT3 mutation was done by polymerase chain reaction (PCR). Cytogenetic analysis show: 85-93. XXYY,inc(cp5)/46,XY. Based on these considerations, we suggest the detection of FLT3 mutations as a diagnostic procedure for all AML patients.",
publisher = "Amer Soc Clinical Pathology, Chicago",
journal = "Laboratory Medicine",
title = "Acute Myeloid Leukemia Associated With Near-Tetraploid Karyotype and Mutations in the FLT3 Gene",
pages = "543-540",
number = "9",
volume = "42",
doi = "10.1309/LM6E0CQQPOKXXG4E"
}

Jurisić, V., Pavlović, S., Čolović, N., Đorđević, V., Janković, G.,& Colović, M.. (2011). Acute Myeloid Leukemia Associated With Near-Tetraploid Karyotype and Mutations in the FLT3 Gene. in Laboratory Medicine
Amer Soc Clinical Pathology, Chicago., 42(9), 540-543.
https://doi.org/10.1309/LM6E0CQQPOKXXG4E

Jurisić V, Pavlović S, Čolović N, Đorđević V, Janković G, Colović M. Acute Myeloid Leukemia Associated With Near-Tetraploid Karyotype and Mutations in the FLT3 Gene. in Laboratory Medicine. 2011;42(9):540-543.
doi:10.1309/LM6E0CQQPOKXXG4E .

Jurisić, Vladimir, Pavlović, Sonja, Čolović, Nataša, Đorđević, Vesna, Janković, Gradimir, Colović, Milica, "Acute Myeloid Leukemia Associated With Near-Tetraploid Karyotype and Mutations in the FLT3 Gene" in Laboratory Medicine, 42, no. 9 (2011):540-543,
https://doi.org/10.1309/LM6E0CQQPOKXXG4E . .